Gero

Gero has done what almost no computational-aging company has managed: convert a contrarian scientific thesis into hard pharma validation, twice. Founded in 2018 by physicist Peter Fedichev, Gero applies statistical physics and dynamical-systems theory — not just pattern-matching machine learning — to human data spanning over 100 million patient records, aiming to separate reversible disease states from the irreversible drift of aging itself. The payoff is external endorsement that money cannot easily buy: a 2023 Pfizer collaboration on fibrotic-disease targets, and in July 2025 a joint research and license agreement with Roche's Chugai Pharmaceutical granting Chugai exclusive worldwide antibody rights against Gero-discovered age-related targets, with up to $250M in milestones plus royalties that could push total deal value past $1B. That is a capital-light, royalty-bearing model: Gero nominates the targets, Chugai's antibody engineers and Pfizer's chemists absorb the ruinous cost of clinical development, and Gero keeps the platform. Being named a World Economic Forum 2026 Technology Pioneer and helping define the emerging field of "gerophysics" (now a Nature Portfolio collection) lends the physics-first approach institutional legitimacy that the supplement-and-testing end of longevity conspicuously lacks. For a company that raised only a modest Series A extension of $6M in 2023, having two of pharma's most demanding partners underwrite its target discovery is an extraordinary capital-efficiency story, and each additional partner deepens a moat built on a genuinely differentiated scientific method rather than compute scale alone.